Nanobiotix Announces Issue of European Patent Protecting Its nanoXray(TM) Anticancer Platform
Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that the European Patent Office (EPO) has issued Patent No. 1744789 to the Company, related to its “novel activable particles that can be used in the health sector.”
More specifically, the patent protects “composite particles that can generate free radicals or heat when excited by X-rays, and to the uses thereof in health, particularly human. The inventive particles comprise an inorganic-based, and optionally organic-based, nucleus and can be activated in vivo, in order to label or alter cells, tissues or organs. (The patent protection) also relates to methods for the production of said particles, and to pharmaceutical or diagnostic compositions containing same.”
“We are extremely pleased that our platform technology, nanoXray, is now patent-protected throughout the European Union. We are hopeful that we will soon receive similar patent protection in the United States as well,” said Laurent Lévy, Ph.D., President and CEO of Nanobiotix and Co-President of the French Technology Platform on Nanomedicine (FTPN). “NanoXray is designed to allow the precise destruction of cancer cells via the controlled application of an outside-the-body energy source — a standard X-ray. Of course, protecting this intellectual property is key to long-term commercial success.”
Other news from the department research and development
